Results 171 to 180 of about 28,214,434 (299)

JAKPOT Prediction Rule for Erythrocytosis: External Validation and Cost-Effectiveness Analysis. [PDF]

Am J Hematol
Lam BD, Ito S, Ryu J, O'Sullivan K, Potnis K, Lu R, Bidikian A, Ng DQ, Singh R, Deter A, Carfagnini C, Bechara S, Kandula M, Do N, Fillmore N, Freed JA, Patell R, La J, Goshua G.   +18 more
europepmc   +1 more source

Association Between Neurofilament Light Chain and Real‐World Ambulatory Function in Progressive MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neurofilament light chain (NfL) is a biomarker of neuroaxonal injury in multiple sclerosis (MS), yet associations with functional outcomes remain unclear. Longitudinal associations between serum NfL (sNfL) and daily step count (STEPS) from wearable devices were assessed in a large international progressive MS cohort.
Gabby B. Joseph, Megan McCune, Riley Bove, Ahmed Abdelhak, Bruce A. C. Cree, Valerie J. Block   +5 more
wiley   +1 more source

Surrogate endpoints in cost-effectiveness analysis for use in health technology assessment - a qualitative analysis. [PDF]

Int J Technol Assess Health Care
Flight L, Salih F, Collins SD, Aung P, Coory M, Ollendorf DA, Richardson M, Garrett Z.   +7 more
europepmc   +1 more source

Subjective Cognitive Concerns and Cognitive Trajectories in Parkinson's Disease: Biomarker Impact

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To examine the relationship of subjective cognitive concerns (SCC) with biomarkers of Alzheimer's disease (AD), neurodegeneration, and Parkinson's disease (PD) and domain‐specific cognitive trajectories among cognitively unimpaired persons with de novo PD. Method Cognitively unimpaired participants with SCC (n = 294) and without SCC (
Francesca V. Lopez, Fareshte Erani, Katherine J. Bangen, David G. Coughlin, Douglas Galasko, Kelsey R. Thomas   +5 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

Integrating clinical and economic outcomes in the elderly myeloma management: a comparative cost-effectiveness analysis. [PDF]

Front Oncol
Solimando AG, Desantis V, Di Marzo L, de Martino G, D'Amore S, Girardi L, Dicuonzo G, Andriano A, Dammacco F, Vacca A, Bilancia M, Ria R.   +11 more
europepmc   +1 more source

A Two‐Stage Plasma Biomarker Algorithm Reduces Amyloid PET Use and the p‐Tau217 Gray Zone

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma p‐Tau217 leaves 30%–50% of patients in an indeterminate “gray zone” often requiring Aβ‐PET. We developed GRAD (Gatekeeper‐Reflex for Alzheimer's Disease), a two‐stage Aβ‐positivity prediction model to improve classification while reserving Aβ‐PET for residual uncertainty.
Harthik Parankusham, Casey Vanderlip, Colin Birkenbihl, Eashwar Krishna, Chizobam Ugboaja, Andrew E. Budson, Brandon Frank, for the Alzheimer's Disease Neuroimaging Initiative   +7 more
wiley   +1 more source

Is Cost-Effectiveness Analysis Unfair? [PDF]

Medical Decision Making, 2004
openaire   +2 more sources

Improving the Diagnostic Accuracy of Plasma Alzheimer's Disease Biomarkers With Objective and Subjective Cognitive Screening

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Blood‐based biomarkers are increasingly used to identify Alzheimer's disease (AD) pathology and may play an important role in early disease screening and participant selection for clinical trials. However, their performance across stages of cognitive impairment remains unclear. This study examined whether plasma biomarkers differ in
Maryam Abdolmaleki, Leslie S. Gaynor, Dandan Liu, Timothy J. Hohman, Katherine A. Gifford, Henrik Zetterberg, Angela L. Jefferson, Corey J. Bolton   +7 more
wiley   +1 more source

Cost-effectiveness analysis of Canada's National Overdose Response Service. [PDF]

BMJ Open
Rioux W, Enns B, Viste D, Ghosh SM.
europepmc   +1 more source